0000000000358375

AUTHOR

A Ferlita

Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease: An 8-Month Prospective Pilot Study

research product

Platelet changes in patients with hepatitis C virus-related liver cirrhosis after directly acting antiviral therapy

Background and Purpose of the study:Thrombocytopenia is the most common haematological abnormality in patients with Liver Cirrhosis and it is caused by multiple factors. This study evaluated platelets (PLT) count changes in patients with HCV related LC after DAAs therapy. Materials and Methods: We enrolled 83 patients with LC. In all patients were evaluated liver function tests and PLT count at baseline (BL), at end of therapy (ET) and three months post treatment (PostT), Elastography and ultrasound (US) at BL, and US at PostT. LC diagnosis was histological in 13 patients, in 71 with liver stiffness >12 kPa. All patients were SVR (58 patients had DAAs therapy without, 25 with Ribavirin).…

research product

Effects of Liraglutide on Metabolic Parameters and Carotid Intima-Media Thickness in Patients with The Metabolic Syndrome: A 12-Month Prospective Pilot Study

Recent research indicates that therapy with the GLP-1 agonist liraglutide in patients with type 2 diabetes mellitus (T2DM) seems to have beneficial actions on blood pressure, lipids, and the atherosclerotic process, which may be independent of its effect on glucose metabolism. However, the effects of liraglutide in subjects with the metabolic syndrome (MetS) are largely unknown. Forty-nine subjects with the MetS (24 men and 25 women, age 65±10 yrs) diagnosed by the AHA/NHLBI criteria were included in a 12-month prospective study. All subjects had T2DM, were naïve to incretin-based therapies, and treated with metformin only. Liraglutide was added at a dose of 0.6 mg subcutaneously daily for …

research product